Vimarsana
Biggest News Aggregation in the World

Patrick Velicitat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Velicitat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Velicitat Today - Breaking & Trending Today

Allecra Therapeutics receives FDA approval for treatment targeting severe UTIs - Vimarsana News

Allecra Therapeutics receives FDA approval for treatment targeting severe UTIs

Published: February 27, 2024

Allecra Therapeutics, a biopharma company developing novel therapies to combat antibiotic resistance, has received FDA approval for its treatment tackling ‘complicated’ urinary tract infections (UTIs).

Source: biopharma-reporter.com
Related Topics:
Patrick VelicitatOmar LahlouIain BuchananCommittee For Medicinal Products HumanEuropean Medicines AgencyUs CongressGenerating Antibiotic Incentives Now ActQualified Infectious Disease ProductsMedicinal ProductsHuman UseBio DevelopmentsMarkets Amp RegulationsEmerging MarketsUrinary Tract InfectionFood And Drug AdministrationClinical Trial
Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority - Vimarsana News

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority

Published: October 5, 2022

Allecra Therapeutics ("Allecra") announced today that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract

Source: finanznachrichten.de
Related Topics:
South AfricaUnited StatesUnited KingdomPatrick VelicitatAndreas KranzuschKeith KayeBeta Lactamases EsblsDivision Of AllergyDrug AdministrationJournal Of The American Medical AssociationRobert Wood Johnson Medical School Rutgers UniversityEuropean UnionEuropean Medicines AgencyAllecra TherapeuticsAmerican Medical AssociationExtended Spectrum Beta LactamasesCentral AmericaSouth AmericaInfectious DiseasesRobert Wood Johnson Medical SchoolRutgers UniversityChief Medical OfficerQualified Infectious Disease ProductFast TrackAndera Partners